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Abstract
Background: The effectiveness of ranibizumab in the treatment of diabetic macular edema has been proven with
large clinical trials. For bevacizumab only two clinical trials have been published and a head-to-head comparison
is lacking to date. However, if proved non-inferior to ranibizumab, use of the off-label bevacizumab could reduce
costs enormously without a loss in visual acuity. A cost-effectiveness study has been designed to substantiate
this hypothesis.
Aim: To compare the effectiveness and costs of 1.25 mg of bevacizumab to 0.5 mg ranibizumab given as monthly
intravitreal injections during 6 months in patients with diabetic macular edema. It is hypothesized that
bevacizumab is non-inferior to ranibizumab regarding its effectiveness.
Design: This is a randomized, controlled, double masked, clinical trial in 246 patients in seven academic trial centres
in The Netherlands.
Outcomes: The primary outcome measure is the change in best-corrected visual acuity (BCVA) in the study eye
from baseline to month 6. Secondary outcomes are the proportions of patients with a gain or loss of 15 letters or
more or a BCVA of 20/40 or more at 6 months, the change in leakage on fluorescein angiography and the change
in foveal thickness by optical coherence tomography at 6 months, the number of adverse events in 6 months, and
the costs per quality adjusted life-year of the two treatments.
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Background
Diabetic retinopathy (DR) is the most important cause
of blindness in the working age population in industrial
countries. In patients with DR, diabetic macular edema
(DME) is the main cause of permanent decrease of vision
[1]. Until recently, the treatment options were focal and
grid laser photocoagulation and intra-vitreal injections
with corticosteroids [2, 3], but their efficacy is limited. The
recent introduction of the anti-VEGF agent ranibizumab
(Lucentis) represents an important improvement in the
treatment of DME. Ranibizumab is a Fab fragment of a
humanized monoclonal antibody against vascular endo-
thelial growth factor-A (VEGF), a major causal factor in
DME [4].
In several large randomized clinical trials [5–8], pa-
tients treated with ranibizumab had a better visual out-
come than those treated with sham injections and/or
laser therapy. Ranibizumab given as monthly injections,
or in an ‘as needed’ scheme, led to a 6–10 letters better
mean visual acuity after 12 months compared to
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control groups. The maximum effect of ranibizumab
was observed around 6 months, after which the effect
stabilized. In addition to its effect on visual acuity,
ranibizumab markedly decreased retinal thickness as
measured by optical coherence tomography (OCT) and
significantly improved patient reported quality of life
parameters.
Bevacizumab (Avastin) is the full length anti-VEGF-A
antibody from which ranibizumab is derived [9]. Bevaci-
zumab has been used off-label on a widespread scale by
ophthalmologists in the US and Europe, and has grad-
ually become standard care in the treatment of DME in
The Netherlands, since the first results of the ranibizu-
mab RCT’s became available in 2009. The efficacy and
safety of bevacizumab 1.25 mg in the treatment of DME
have been demonstrated in a number of case series and
two RCTs [10]. Bevacizumab was found to improve vis-
ual acuity by approximately 8 letters at 3–12 months
follow up [11, 12]. Bevacizumab markedly reduced ret-
inal thickness on OCT, to a similar extent as reported
for ranibizumab [11, 12].
Conclusive evidence from randomized controlled trials
(RCT) directly comparing bevacizumab and ranibizumab
is lacking.
Nepomuceno et al. recently completed a head to head
comparison in 63 eyes. Patients were treated monthly if
the central retinal field thickness was more than 275 μm
with either bevacizumab or ranizumab for one year. They
observed a significant improvement in both groups at all
study visits. The improvement was significantly greater in
the ranibizumab group compared with the bevacizu-
mab group at week 8 and 32. There was no significant
difference in decrease in central retinal thickness. The
mean number of injections was significantly higher in
the bevacizumab group (9.84) than in the ranibizumab
group (7.67) [13].
At this moment two other trials are ongoing.
NCT01627249 is a single blind study comparing the ef-
fectiveness of intravitreal aflibercept, bevacizumab and
ranibizumaf for DME. Six hundred sixty patients will be
treated over a one year time frame. The primary out-
come is change in BCVA. The secondary outcome is the
number of injections.
The other trial, NCT01610557 is a double blind com-
parison of ranibizumab as monotherapy and ranibizu-
mab and bevacizumab consecutively.
Finally there was a double blind trial, NCT00545870,
comparing bevacizumab to ranibizumab for diabetic ret-
inopathy in 60 patients. However it has been suspended.
The costs of bevacizumab are 20 - to 40 fold lower
than the costs of ranibizumab, and it has been estimated
that in the Netherlands alone, the costs of ranibizumab
treatment of DME would be around 10–15 million Euros
higher than treatment with bevacizumab.
Methods
Design
The BRDME study is a multicenter, randomized, double-
masked comparative clinical trial.
Patient population
All patients with vision loss due to DME and foveal thick-
ening (as determined on OCT) that may benefit from
anti-VEGF treatment are potentially eligible for the study
(Tables 1 and 2).
Randomization, blinding and treatment allocation
Included patients are randomized to receive either beva-
cizumab or ranibizumab.
Patient, treating physician, and evaluating investigator
staff are blinded for treatment allocation. Study medication
is repackaged in masked syringes at the local pharmacy.
The randomization procedure is computer- and web
based, using permuted blocks and stratified by centre,
BCVA of the study eye (52 letters or less versus 53 let-
ters or more), and BCVA of the non-study eye (52 let-
ters or less versus 53 letters or more). Randomization is
made available by the AMC Clinical Research Unit.
Randomization code breaking information and sheets
for emergency use only is kept in the local hospital safe.
Indications to break the randomization code are not
predefined.
Intervention
Study procedures
At the baseline visit, the patient signs the written informed
consent form, and the medical and ophthalmic history is
taken. Within 14 days after randomization the patient re-
ceives the first intravitreal injection of the study drug. In-
vestigations and measurements of the BRDME trial are
carried out according to the following diagram.
During each visit, vital signs (pulse and blood pres-
sure), concomitant medication and adverse events are
recorded. BCVA is assessed and an OCT examination is
performed by certified personnel prior to the intravitreal
injection. The interval between visits is 30 days, ±7 days
Table 1 Inclusion criteria
1. patients > 18 years of age who have signed an informed consent.
2. Type 1 or Type 2 diabetes mellitus with glycosylated haemoglobin
(HbA1c) less than 12.0 % at screening. Treatment for diabetes must have
been stable for at least 2 months.
3. Patients with visual impairment due to DME with a central area
thickness >325 μm, who are eligible for anti-VEGF treatment
according to the investigator. If both eyes are eligible, the one with
the worse visual acuity, as assessed at visit 1, is selected by the
investigator as the study eyes
4. BCVA equal or more than 24 and less or equal to 78 letters in the
study eye at screening using ETDRS-like visually acuity testing charts
at a testing distance of 4 m.
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to allow for flexibility in scheduling. At baseline and
6 months, an ophthalmic exam and fluorescein angiog-
raphy are performed. At baseline, 3 and 6 months patients
are asked to complete a short, 16-item questionnaire on
health status (EQ-5D), health care resource utilization,
and out-of-pocket expenses (shortened Health and Labour
questionnaire) (Table 3).
Primary outcome
The primary outcome is the mean change in best-corrected
visual acuity (BCVA) in the study eye from baseline to
month 6.
Secondary outcomes
 the difference between ranibizumab and
bevacizumab in their effect on retinal vascular
leakage and edema as determined by FA and OCT
at 6 months
 the proportions of dropouts in the two treatment
arms before the final 6 months assessment
Table 2 Exclusion criteria
Women of child-bearing potential, unless they are using two birth
control methods.
Pregnant or nursing (lactating) women.
Inability to comply with study procedures.
Active intraocular inflammation (grade + or above) in either eye at
enrolment.
Any active infection in either eye at the time of enrolment.
History of uveitis in either eye at any time.
Structural damage within 600 μm of the centre of the macula in the
study eye likely to preclude improvement in visual acuity following in
the resolution of macular edema, including atrophy of the retinal
pigment epithelium, subretinal fibrosis, laser scar(s), epiretinal membrane
involving fovea or organized hard exudate plaques.
Uncontrolled glaucoma in the study eye at screening (IOP > 24 mmHg
on medication or according to investigator’s judgment).
Neovascularization of the iris in the study eye.
Evidence of vitreomacular traction in the study eye.
Active untreated proliferative diabetic retinopathy in the study eye.
Any intraocular surgery in the study eye within 3 months prior to
randomization.
History of vitrectomy in study eye regardless of time prior to
randomization.
Planned medical or surgical intervention during the 6 months study
period.
Panretinal laser photocoagulation in the study eye within 3 months
prior to or during the study.
Focal/grid laser photocoagulation in the study eye 3 months prior to
study entry.
Treatment with anti-angiogenic drugs in the study eye within 3 months
prior to randomization.
Use of other investigational drugs at the time of enrolment, or within
3 month or 5 half-lives from enrolment, whichever is longer.
History of intravitreal corticosteroids in phakic eye within 18 months
prior to randomization or in post-cataract surgery study eye within
4 months prior to randomization.
Ocular conditions in the study eye that require chronic concomitant
therapy with topical ocular or systemically administered corticosteroids.
History of stroke or transient ischemic attack (TIA) within 6 months prior
to enrolment.
Renal failure requiring dialysis or renal transplant or renal insufficiency
with creatinine levels > 2.0 mg/dl at screening.
Blood pressure systolic > 165 mm Hg or diastolic > 105 mmHg at
screening and randomization.
Hypertension or change in antihypertensive treatment within 1 month
preceding randomization.
Current use of or likely need for systemic medications known to be
toxic to the lens, retina or optic nerve, including deferoxamine,
chloroquine/hydroxychloroquine (Plaquenil), tamoxifen, phenothiazines
and ethambutol.
Known hypersensitivity to fluorescein, ranibizumab or bevacizumab or
any component thereof or drugs of similar chemical classes.
Any type of advanced, severe or unstable disease or its treatment, that
may interfere with primary and/or secondary variable evaluations
including any medical condition that could be expected to progress,
recur, or change to such an extent that it may bias the assessment of
Table 2 Exclusion criteria (Continued)
the clinical status of the patient to a significant degree or put the
patient at special risk.
Concomitant conditions in the study eye which would, in the opinion
of the investigator, prevent the improvement of visual acuity on study
treatment.
Ocular disorders in the study eye that may confound interpretation of
study results, compromise visual acuity or require medical or surgical
intervention during the 6-month study period, including cataract,
retinal vascular occlusion, retinal detachment, macular hole, or choroidal
neovascularization of any cause (e.g., AMD, ocular histoplasmosis, or
pathologic myopia)
Table 3 Study flow chart
Assessment/ Phase Treatment
procedure Visit 1 2 3 4 5 6 7 8
Month 0 1 2 3 4 5 6
Check inclusion/exclusion criteria X
Informed consent X
Medical History X
Vital Signs X X X X X X X
Check concomitant medications X X X X X X X X
Check adverse events X X X X X X X
EQ-5D or HUI-3 questionnaire X X X
Blood sample X
Drug administration X X X X X X
BCVA X X X X X X X X
Ophthalmic exam X X X
Fluorescein angiography X X
Optical coherence tomography X X X X X X X X
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 the proportions of BCVA gainers, BCVA losers and
OCT/FA non-responders in the two treatment arms
at the 6 month assessment
 the difference in the occurrence of (serious) adverse
events in the 6 months study period
 the difference in costs and costs per quality adjusted
life-year between the two treatment strategies over
the 6 months treatment period
Ethics and funding
The study adheres to the tenets of the Declaration of
Helsinki. The trial protocol has been approved by the
Medical Ethical Committee of the Academic Medical
Center (Amsterdam). The participation of the other cen-
ters is reviewed at each center according to Dutch law.
Registration of the trial was requested June 28, 2012 at
clinicaltrials.gov. NCT01635790. The study is ongoing.
At the time of submission there were no publications of
this trial.
The sponsor of this trial is the Netherlands Organisa-
tion for Health Research and Development, ZonMW.
The study design has been peer reviewed. There is no
contribution of commercial organisations.
Data safety and monitoring board
A Data Safety Monitoring Board is installed and can rec-
ommend the steering committee of the BRDME trial to
terminate the study before completion depending on the
level of discrepancy between both study arms in inci-
dences of (serious) adverse events and numbers of patients
who terminate the initially assigned drug prematurely.
The DSMB members are independent and have no
competing interests related to any intervention in the
BRDME trial. The DSMB is composed of two members
with relevant clinical expertise and one member with a
background in statistics.
Sample size
The difference in the BCVA change scores from baseline
at month 6 is tested statistically for non-inferiority. Start-
ing from a common standard deviation - based on obser-
vations in previous trials with ranibizumab in DME - of
the change in BCVA score of 11 letters in both groups,
and assuming an improvement from baseline of 6–8 let-
ters in both the ranibizumab group and the bevacizumab
group, a sample size of 246 patients (123 in each group)
has an 80 % power of demonstrating non-inferiority by
excluding a difference of 3.5 letters or more, using a one-
sided Student’s T-test and a significance level of 0.05. The
mean improvement of 7 letters is the average of the
changes observed in the placebo-controlled trials dis-
cussed earlier. The margin of non-inferiority is equivalent
to less than half this improvement.
Statistical analyses
According to the intention-to-treat principle all random-
ized patients are included in the final analyses.
The primary outcome measure is the change in best-
corrected visual acuity (BCVA) from baseline to month
6 as assessed with ETDRS-like VA charts. When visual
acuity is measured in this manner, a 15 letter gain means
a doubling of the visual acuity, and a 15 letter loss means
that acuity is halved. As the measure of effectiveness, the
mean BCVA score at month 6 in the ranibizumab group
is compared with the mean score in the bevacizumab
group, corrected for baseline differences. The confidence
interval for the difference in mean BCVA change scores
are reported. We also test statistically for non-inferiority
of bevacizumab to ranibizumab using the T-test for inde-
pendent samples.
Ecomomic evaluation
If the non-inferiority of bevacizumab to ranibizumab can
be demonstrated, then the economic evaluation will be
performed as a cost-minimization analysis from a societal
perspective. If bevacizumab turns out to be inferior, then
the question arises whether the health losses are in rea-
sonable balance with the expected cost savings. In that
situation a cost-utility analysis will be performed with the
cost per quality-adjusted life-year as outcome parameter.
The analysis will be based on (i) the observed cost and vis-
ual acuity data, and (ii) available and upcoming literature
on health utility associated with different levels of visual
acuity. [14, 15] If a cost-utility analysis seems opportune,
sensitivity analyses will be done to study the robustness of
using patient-based preferences instead of general popula-
tion based preferences in order to derive health utilities.
The latter ones will be reported as the main outcome.
Costs will include the direct medical costs of diagnosis
and treatment restricted to (potential) vision loss, includ-
ing the use of visual aids. Only the medical costs attribut-
able to loss of vision or the prevention thereof will be
included in this population with a high risk of co-morbid
conditions. Costs will be estimated as the product-sum of
the volumes of resources used and their respective unit
costs. The cost items will include visits to the health care
providers (e.g., ophthalmologist, optometrists, and general
practitioners), medication use, and ophthalmic equipment
for imaging (Digital Imaging Systems, Fundus Camera’s,
Optical Coherence Tomography) and operating theatres.
Patient-related costs will include the costs of health-
related travel and over-the-counter medication. In this
population data on loss of productivity will also be col-
lected. The use of resources will be documented in the
case record forms and by an additional questionnaire to
be completed at baseline and at 3-monthly intervals by
the study participants. Unit costing will be based on the
national guideline on costing in health care research, [16]
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supplemented by mean local unit costing data from par-
ticipating reference centres and practices. Unit costs will
be based on relevant national guide prices (Farmacothera-
peutisch kompas, G-standaard van de Z-index).
The base year for costing will be 2013. Unit costs will
be price-indexed when originating from other calendar
years using general yearly price-indices [7].
The time horizon of the economic evaluation will be
6 months. No discounting of costs (and effects) will be
performed.
Discussion
Implementing a first line therapy with bevacizumab for
patients with diabetic macular edema could reduce
costs enormously. First, we have to investigate in a well
designed head-to-head comparison whether or not
both medicines are equally effective, or at least, bevaci-
zumab is not inferior to ranibizumab. For age-related
macular degeneration clinical trials have demonstrated
non-inferiority [17–20] We cannot extrapolate these
results to DME because the mechanism of vision loss
in DME by intraretinal edema in diabetes is not the
same as that of subretinal neovascularization and scar-
ring as in macular degeneration.
We could have included aflibercept in our comparison
too. At the time we designed the study there was very
limited data about this medicine. We would need to
enrol many more patients to be able to perform the
comparison which is at present not feasible.
Summary
In order to determine the best first line anti-VEGF medi-
cine in the treatment of DME we decided to set up a
head-to-head comparison with monthly injections during
six months. The primary clinical target is the improve-
ment of best corrected visual acuity, while the primary
health economic target is cost reduction without a loss in
health gain as measured by a change in visual acuity or by
quality adjusted life years.
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